Jieyi Wang

1.5k total citations · 1 hit paper
28 papers, 1.2k citations indexed

About

Jieyi Wang is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jieyi Wang has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Molecular Biology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jieyi Wang's work include Peptidase Inhibition and Analysis (9 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Jieyi Wang is often cited by papers focused on Peptidase Inhibition and Analysis (9 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Jieyi Wang collaborates with scholars based in United States, United Kingdom and China. Jieyi Wang's co-authors include Lukasz K. Chlewicki, Haidong Tang, Yang‐Xin Fu, Yang Wang, Yuan Zhang, Wei Liang, Xiaoxiao Wang, Jingya Guo, Lora A. Tucker and George S. Sheppard and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Jieyi Wang

28 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

2016 382 citations Haidong Tang, Yang Wang et al. Cancer Cell profile →

Peers

Jieyi Wang

ONCOL

IMMUN

PRM

Phuong L. Doan United States

Emilio Barberá‐Guillem Spain

W. E. Berdel Germany

JEFF EVANS United Kingdom

Miriam Redrado Spain

Mike F. Burbridge France

Nicolas Floc’h United Kingdom

Ángel Santiago Mexico

Lynsey A. Huxham Canada

Ryuji Maekawa Japan

Phuong L. Doan United States

Jieyi Wang

258 ×0.4

ONCOL

624 ×1.5

288 ×0.8

IMMUN

136 ×0.9

PRM

199 ×1.4

Citations per year, relative to Jieyi Wang Jieyi Wang (= 1×) peers Phuong L. Doan

Countries citing papers authored by Jieyi Wang

Since Specialization

Citations

This map shows the geographic impact of Jieyi Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jieyi Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jieyi Wang more than expected).

Fields of papers citing papers by Jieyi Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jieyi Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jieyi Wang. The network helps show where Jieyi Wang may publish in the future.

Co-authorship network of co-authors of Jieyi Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Jieyi Wang. A scholar is included among the top collaborators of Jieyi Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jieyi Wang. Jieyi Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Mengke, Xin Zhang, Xin Xu, et al.. (2024). Effect of interaction between dissolved organic matter and iron/manganese (hydrogen) oxides on the degradation of organic pollutants by in-situ advanced oxidation techniques. The Science of The Total Environment. 918. 170351–170351. 19 indexed citations

Zhou, Yan, Xianan Li, Linqing Li, et al.. (2024). An open label, phase 1b/2 trial of LVGN6051 (4-1BB agonistic antibody) combined with anlotinib for refractory soft tissue sarcoma (STS).. Journal of Clinical Oncology. 42(16_suppl). 11554–11554. 1 indexed citations

Liu, Luyan, et al.. (2022). Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking. Frontiers in Pharmacology. 13. 924197–924197. 14 indexed citations

Qi, Xinyue, Fanlin Li, Yi Wu, et al.. (2019). Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nature Communications. 10(1). 2141–2141. 98 indexed citations

Bardwell, Philip D., Matthew Staron, Junjian Liu, et al.. (2017). Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig. Protein & Cell. 9(1). 121–129. 11 indexed citations

Vaidya, Kedar S., Anatol Oleksijew, Lora A. Tucker, et al.. (2017). A “Prozone-Like” Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor. Pharmacology. 100(5-6). 229–242. 4 indexed citations

Wang, Jieyi, Mark G. Anderson, Anatol Oleksijew, et al.. (2016). ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET –Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence. Clinical Cancer Research. 23(4). 992–1000. 104 indexed citations

Tang, Haidong, Yang Wang, Lukasz K. Chlewicki, et al.. (2016). Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell. 29(3). 285–296. 382 indexed citations breakdown →

Wang, Jieyi, Liliane Goetsch, Lora A. Tucker, et al.. (2016). Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 16(1). 105–105. 50 indexed citations

10.

Pappano, William N., et al.. (2014). Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells. BMC Cancer. 14(1). 430–430. 25 indexed citations

11.

Gu, Jinming, Jinsong Yang, Qing Chang, et al.. (2014). Identification of Anti-ErbB2 Dual Variable Domain Immunoglobulin (DVD-Ig™) Proteins with Unique Activities. PLoS ONE. 9(5). e97292–e97292. 14 indexed citations

12.

Fidanze, Steve, Scott Erickson, Gary T. Wang, et al.. (2010). Imidazo[2,1-b]thiazoles: Multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 20(8). 2452–2455. 50 indexed citations

13.

Pappano, William N., Paul Jung, Jonathan A. Meulbroek, et al.. (2009). Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605. BMC Cancer. 9(1). 314–314. 14 indexed citations

14.

Hubbard, Robert D., Nwe Y. BaMaung, Steve Fidanze, et al.. (2009). Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 19(6). 1718–1721. 17 indexed citations

15.

Wilsbacher, Julie L., Qian Zhang, Lora A. Tucker, et al.. (2008). Insulin-like Growth Factor-1 Receptor and ErbB Kinase Inhibitor Combinations Block Proliferation and Induce Apoptosis through Cyclin D1 Reduction and Bax Activation. Journal of Biological Chemistry. 283(35). 23721–23730. 22 indexed citations

16.

Wang, Gary T., Robert A. Mantei, Megumi Kawai, et al.. (2007). Lead optimization of methionine aminopeptidase-2 (MetAP2) inhibitors containing sulfonamides of 5,6-disubstituted anthranilic acids. Bioorganic & Medicinal Chemistry Letters. 17(10). 2817–2822. 14 indexed citations

17.

Kawai, Megumi, Nwe Y. BaMaung, Steve Fidanze, et al.. (2006). Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorganic & Medicinal Chemistry Letters. 16(13). 3574–3577. 41 indexed citations

18.

Sheppard, George S., Jieyi Wang, Megumi Kawai, et al.. (2004). 3-Amino-2-hydroxyamides and related compounds as inhibitors of methionine aminopeptidase-2. Bioorganic & Medicinal Chemistry Letters. 14(4). 865–868. 37 indexed citations

19.

Gwaltney, Stephen L., Kenneth J. Barr, Qun Li, et al.. (2001). Novel sulfonate analogues of combretastatin A-4. Bioorganic & Medicinal Chemistry Letters. 11(7). 871–874. 49 indexed citations

20.

Nienaber, V., Donald J. Davidson, Rohinton Edalji, et al.. (2000). Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite. Structure. 8(5). 553–563. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact